Do DTC Television Ads Really Need To List All Drug Risks?
This article was originally published in The Pink Sheet Daily
FDA study aims to determine the impact of limiting Rx drug risk info in TV ads to those that are “serious and actionable.”
You may also be interested in...
Agency is considering whether drug broadcast ads should note only risks that are severe, serious or actionable; FDA study finds this limitation improves risk recall and recognition of benefits.
Flurry of new studies brings tally of FDA research projects on Rx drug promotion to 43; the 14 in progress and 7 pending peer review or recently published have a total cost of $15.5m.
Viewers retain more risks and benefits in DTC ads showing only limited risk information, but experts predict it may not result in substantial change right away.